GET DAILY SIGNALSWhy Is Stryker Corporation (SYK) Stock Down -6.38% Today?
Key Takeaways
- SYK shares fell roughly 6.4% after the company reported third-quarter results that missed Wall Street expectations and cut its full-year outlook.
- The primary catalyst was an earnings-driven selloff: revenue of $6.52 billion missed the $6.62 billion consensus, and adjusted EPS of $3.52 came in below the $3.55 expected.
- A downward revision to 2026 guidance compounded the pressure, with organic sales growth now seen at 6.5%–7.0%, down from a prior range of 8.3%–9.3%.
- Secondary drivers included soft hip and knee volumes, lingering supply-chain disruption from an earlier cyberattack, and slower adoption of newer products such as Mako RPS and Triathlon Gold.
- Analysts reacted by trimming price targets, reinforcing the negative market reaction.
- Traders are now watching fourth-quarter execution, 2027 guidance under incoming CEO Spencer Stiles, and whether surgical volumes stabilize.
- For additional details on valuation and targets, explore Price Targets, Earnings, and Forecast pages for SYK.
- To discover the strongest-performing automated strategies under current market conditions, explore Trending AI Robots.
Opening Summary
Stryker Corporation (SYK), a global medical technology company known for orthopaedic implants, surgical equipment, and neurotechnology devices, saw its shares fall sharply on Friday. The stock traded down approximately 6.38%, slipping from a prior close of $311.75 to around $291.87. The decline came after the company reported third-quarter results that missed analyst expectations and lowered its full-year sales and earnings guidance, triggering a broad market selloff in the stock.
Earnings Miss Weighs on the Stock
The immediate driver behind the move was a third-quarter earnings report that fell short of forecasts. Stryker posted revenue of $6.52 billion, up 7.7% year over year but below the $6.62 billion analysts had projected. Adjusted earnings per share came in at $3.52, a roughly 10% increase from the prior-year period but slightly under the $3.55 consensus estimate.
While the magnitude of the headline miss was modest, the market's reaction was outsized because the shortfall touched both the top and bottom lines and was accompanied by a weaker forward view. Net profit on a GAAP basis also declined, reflecting both softer operating performance and a goodwill impairment charge.
Guidance Cut Amplifies the Selloff
The more significant catalyst was management's decision to reduce its outlook. The company now expects 2026 organic net sales growth of 6.5% to 7.0%, down from a prior range of 8.3% to 9.3%. It also trimmed its adjusted EPS forecast to a range of $14.80 to $14.90, below the previous $14.95 to $15.10 and under the consensus estimate near $14.95.
CEO Kevin Lobo acknowledged that the quarter's "good overall performance" nonetheless "fell short" of internal expectations. The guidance reset signaled that headwinds in core orthopaedic markets, rather than being transitory, are expected to persist through the end of the year, prompting investors to reassess the company's near-term growth trajectory.
Segment Weakness and Operational Headwinds
Under the surface, the results revealed uneven performance across divisions. The MedSurg and Neurotechnology segment grew 9.2%, a bright spot driven by strength in endoscopy and medical products. However, the Orthopaedics segment grew just 5.7%, with U.S. knee sales up only 1.3% and U.S. hip sales down 0.6%.
Management cited elevated insurance premiums and deductibles, increased pre-authorization denials, and softer international markets as factors slowing surgical volumes. Lingering supply disruption tied to an earlier cyberattack and slower-than-expected adoption of newer offerings such as Mako RPS and Triathlon Gold added further friction. These issues collectively reinforced concerns that growth is decelerating even as management works to restore momentum.
Analyst Reactions and Market Context
The market reaction was accompanied by a wave of analyst revisions. Several firms trimmed price targets while largely maintaining their ratings, reflecting a more cautious stance on the stock following the guidance cut. The move also occurred against a backdrop in which the broader medical-device sector has faced questions about procedure volume trends and cost pressures.
Trading activity was elevated as investors repositioned, with the stock underperforming the broader market. The decline pushed shares toward levels last seen near the stock's 52-week low, underscoring the magnitude of the de-rating relative to its recent trading range.
What Comes Next for SYK
Looking ahead, attention turns to fourth-quarter execution and whether the company can stabilize hip and knee volumes while sustaining momentum in MedSurg and Neurotechnology. Investors will also focus on the leadership transition, as incoming CEO Spencer Stiles takes over and is expected to provide clearer 2027 guidance early next year.
Key risks include continued softness in surgical procedures, the pace of recovery from the cyberattack-related supply disruption, and the trajectory of newer product launches. While the company maintains a strong balance sheet and a sizable share-buyback program, the path to regaining investor confidence will depend on delivering results that match or exceed its reset expectations.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that have demonstrated standout performance in the current market environment. Tickeron offers hundreds of automated strategies spanning thousands of tickers, each varying by trading style, timeframe, performance metrics, and the symbols they trade. Only the strongest performers under prevailing conditions are featured. Explore the Trending AI Robots page to see which strategies are leading right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
SYK in +3.43% Uptrend, rising for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SYK advanced for three days, in 173 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on SYK as a result. In 51 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.
The Moving Average Convergence Divergence (MACD) for SYK just turned positive on September 28, 2026. Looking at past instances where SYK's MACD turned positive, the stock continued to rise in 23 of 44 cases over the following month. The odds of a continued upward trend are 52%.
SYK moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SYK crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
The Aroon Indicator entered an Uptrend today. In 128 of 258 cases where SYK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
Bearish Trend Analysis
The 10-day RSI Indicator for SYK moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 26 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
SYK broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.985) is normal, around the industry mean (3.870). P/E Ratio (32.040) is within average values for comparable stocks, (1.382). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.052). Dividend Yield (0.011) settles around the average of (0.010) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of reconstructive, medical and surgical, and neurotechnology and spine products
Industry MedicalNursingServices
Advertisement